Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
Aged
Biomarkers
/ blood
Computed Tomography Angiography
Coronary Angiography
Coronary Artery Disease
/ blood
Female
Follow-Up Studies
Humans
Incidence
Japan
/ epidemiology
Male
Middle Aged
Multidetector Computed Tomography
/ methods
Proprotein Convertase 9
/ blood
Retrospective Studies
Risk Assessment
/ methods
Risk Factors
Severity of Illness Index
Coronary artery disease
Multidetector-row computed tomography
Pro-protein convertase subtilisin/kexin type 9
Statin
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
13
04
2018
accepted:
29
06
2018
pubmed:
6
7
2018
medline:
21
3
2019
entrez:
6
7
2018
Statut:
ppublish
Résumé
The ability of pro-protein convertase subtilisin/kexin type 9 (PCSK9) levels to predict the presence or severity of coronary artery disease (CAD) remains controversial. The purpose of this study was to investigate these associations. We enrolled 393 patients who were clinically suspected to have CAD or who had at least one cardiac risk factor and underwent multidetector-row computed tomography coronary angiography. The presence of CAD (≥50% coronary stenosis), the number of significantly stenosed coronary vessels, and plasma levels of PCSK9 by ELISA were analyzed. Plasma PCSK9 levels (log-transformed data) were significantly associated with the presence of CAD. Next, we divided the patients into two groups (non-statin and statin groups) according to statin treatment. PCSK9 levels in the non-statin group were significantly lower than those in the statin group. There were no significant differences in PCSK9 levels between the absence and presence of CAD in the statin group. However, in the non-statin group, PCSK9 levels in patients with CAD were significantly higher than those in patients without CAD. PCSK9 levels, in addition to age, gender, BMI, DM and HDL-C, were independently associated with the presence of CAD by a multivariable analysis. In conclusion, our results demonstrated that plasma PCSK9 levels may be a marker for evaluating the presence of CAD.
Identifiants
pubmed: 29974199
doi: 10.1007/s00380-018-1218-1
pii: 10.1007/s00380-018-1218-1
doi:
Substances chimiques
Biomarkers
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-28Commentaires et corrections
Type : ErratumIn
Références
Circulation. 2000 Mar 14;101(10):1102-8
pubmed: 10715255
Semin Nephrol. 2002 Nov;22(6):449-58
pubmed: 12430089
J Lipid Res. 2003 Nov;44(11):2109-19
pubmed: 12897189
Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5
pubmed: 15118091
Circ J. 2004 Jun;68(6):515-9
pubmed: 15170084
Am J Cardiol. 2006 Jan 15;97(2):173-4
pubmed: 16442357
N Engl J Med. 2006 Mar 23;354(12):1264-72
pubmed: 16554528
Circ J. 2006 Sep;70(9):1122-7
pubmed: 16936422
J Lipid Res. 2008 Feb;49(2):394-8
pubmed: 18033751
Arterioscler Thromb Vasc Biol. 2009 May;29(5):684-90
pubmed: 19265033
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43
pubmed: 19351729
Clin Res Cardiol. 2010 Jan;99(1):45-50
pubmed: 19763659
J Lipid Res. 2010 Jun;51(6):1486-95
pubmed: 20048381
J Lipid Res. 2010 Sep;51(9):2714-21
pubmed: 20525997
J Am Coll Cardiol. 2010 Jun 22;55(25):2833-42
pubmed: 20579540
J Atheroscler Thromb. 2011;18(2):83-8
pubmed: 21307610
J Clin Hypertens (Greenwich). 2011 Mar;13(3):198-204
pubmed: 21366851
Intern Med. 2011;50(12):1279-85
pubmed: 21673462
Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1585-95
pubmed: 22580899
J Lipid Res. 2012 Dec;53(12):2515-24
pubmed: 22811413
Clin Res Cardiol. 2013 Jul;102(7):495-503
pubmed: 23519584
Int J Cardiol. 2014 Jul 1;174(3):863-4
pubmed: 24801085
PLoS One. 2014 Sep 02;9(9):e106294
pubmed: 25180781
Glob Heart. 2015 Dec;10(4):301-311.e11
pubmed: 26014657
Cardiovasc Res. 2015 Sep 1;107(4):556-67
pubmed: 26092101
Ann Med. 2015;47(5):386-93
pubmed: 26153823
Diabetes Obes Metab. 2015 Nov;17(11):1042-55
pubmed: 26183252
Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2254-9
pubmed: 26293463
Eur Heart J. 2016 Feb 7;37(6):554-60
pubmed: 26508163
Heart Lung Circ. 2016 May;25(5):520-5
pubmed: 26706651
Medicine (Baltimore). 2015 Dec;94(52):e2426
pubmed: 26717403
Circulation. 2016 Mar 29;133(13):1230-9
pubmed: 26896437
Atherosclerosis. 2016 May;248:117-22
pubmed: 27015246
Eur Rev Med Pharmacol Sci. 2016;20(6):1135-9
pubmed: 27049268
Eur Heart J Cardiovasc Pharmacother. 2016 Jan;2(1):44-53
pubmed: 27533061
Heart Lung Circ. 2016 Oct;25(10):975-81
pubmed: 27634241
Int J Cardiol. 2017 Jan 15;227:61-65
pubmed: 27846466
Ann Clin Biochem. 2018 Jan;55(1):158-164
pubmed: 28166668
J Atheroscler Thromb. 2017 Sep 1;24(9):895-907
pubmed: 28804094
Circulation. 1988 Nov;78(5 Pt 1):1167-80
pubmed: 3180376
Am J Cardiol. 1986 May 30;57(14):5G-10G
pubmed: 3487242
JAMA. 1995 Jul 12;274(2):131-6
pubmed: 7596000